MedTrace Logo

Effect of Medical Cannabis for Non-motor Symptoms of Parkinson's Disease

NCT05106504 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-11-03

No results posted yet for this study

Summary

Medical cannabis (MC) is a standard treatment in Israel to Parkinson's disease (PD) patients suffering from pain. Nevertheless, it is not known about MC effectiveness for other non-motor symptoms of the disease. Our aim is to prospectively observe patients with PD before and after initiation of MC, for non-motor symptoms effect. In specific, relying of data from multiple sclerosis patients and basic science showing cannabinoid receptor 1 (CB1) is abundantly expressed in the sub epithelial layer of the bladder, we will explore the impact of MC on bladder function and urinary symptoms.

Conditions

  • Bladder, Overactive
  • Parkinson Disease

Interventions

DRUG

Medical Cannabis

Patients will be assessed before and after use of Medical cannabis via inhaled dried buds or sublingual oil extract

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Saar Anis, MD · Sheba Medical Center, Ramat-Gan, Israel

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-02
Primary Completion
2023-08-31
Completion
2024-08-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05106504 on ClinicalTrials.gov